Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 11,500 | |||
2 mg | 在庫あり | ¥ 16,000 | |||
5 mg | 在庫あり | ¥ 25,500 | |||
10 mg | 在庫あり | ¥ 42,000 | |||
25 mg | 在庫あり | ¥ 86,000 | |||
50 mg | 在庫あり | ¥ 130,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 25,500 |
説明 | Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3. |
ターゲット&IC50 | VEGFR2:25 nM |
別名 | BMS-540215 |
分子量 | 370.38 |
分子式 | C19H19FN4O3 |
CAS No. | 649735-46-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 3 mg/mL (8.09 mM)
DMSO: 69 mg/mL (186.3 mM)
H2O: <1 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Brivanib 649735-46-6 Angiogenesis Autophagy JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR FGFR VEGFR inhibit BMS540215 Vascular endothelial growth factor receptor BMS 540215 BMS-540215 Inhibitor inhibitor